Navigation Links
Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com
Date:7/14/2014

Dallas, TX (PRWEB) July 14, 2014

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person’s symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

Complete Report Available at http://www.reportsnreports.com/reports/292055-epicast-report-acute-coronary-syndrome-acs-epidemiology-forecast-to-2023.html .

This report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2013 to 2023 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The epidemiological patient forecast includes:

  •     Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA
  •     ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA
  •     ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA
  •     Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2013 to 2023 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK)

In the 7MM, the hospitalized incident cases of ACS will increase from 1.29 million cases in 2013 to 1.47 million cases in 2023 at the rate of 1.40% per year. The US constitutes around 40% of the total hospitalized incident ACS cases in the 7MM and will be the market with the highest number of cases during the forecast period. The majority of the cases occurred in men (58.15%) and in those ages =65 years (69.34%). For the 7MM, about 33% of the ACS cases were STEMI, 44% were NSTEMI, and 23% were UA. The proportions varied depending on the market.

Order a purchase copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=292055

Reasons to buy

  •     Develop business strategies by understanding the trends shaping and driving the global ACS market.
  •     Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
  •     Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for ACS therapeutics in each of the markets covered.
  •     Identify the number of ACS cases survived to key time periods.

1 Table of Contents

2 Introduction
2.1 Catalyst
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends - MI
3.4 Global Trends - UA
3.5 Forecast Methodology
3.6 Epidemiological Forecast for ACS (2013-2023) - Hospitalized Incident Cases
3.7 Epidemiological Forecast for MI (2013-2023) - Prevalent Cases
3.8 Discussion

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.3 About GlobalData
4.4 About EpiCast
4.5 Disclaimer

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for CHD and ACS
Table 2: Germany, MI Incidence and Re-Infarction Rates (Cases per 100,000 Population), 1985-1987 and 2001-2003
Table 3: Spain, MI Incidence Rate (Cases per 100,000 Population) and Incidence Trends, 2000 and 2013
Table 4: England and Scotland, Temporal Trends in the MI Incidence (Cases per 100,000 Population), 2002-2010
Table 5: 7MM, Summary of STEMI and NSTEMI In-Hospital and One-Year Case-Fatality Rates
Table 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants
Table 7: 7MM, Sources of MI and UA Incidence Data
Table 8: 7MM, Sources of Diagnosed Prevalence Data for MI
Table 9: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Hospitalized Cases of MI
Table 10: 7MM, Hospitalized Incident Cases of ACS, Ages =25 Years, Both Sexes, N (Col %), Selected Years, 2013-2023
Table 11: 7MM, Age-Specific Hospitalized Incident Cases of ACS, Both Sexes, N (Row %). 2013
Table 12: 7MM, Sex-Specific Hospitalized Incident Cases of ACS, Ages =25 Years, N (Row %), 2013
Table 13: 7MM, Hospitalized Incident Cases of ACS Segmented by STEMI, NSTEMI, and UA (N, Row %), Ages =25 Years, Both Sexes, 2013

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/acute-coronary-syndrome/epidemiology-forecast2023/prweb12015229.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. GW researchers: Acute kidney injury and chronic kidney disease as interconnected syndromes
2. Citing urgent, acute mental health issues, especially in Africa, experts petition govts to act
3. Negative iron balance predicts acute heart failure survival
4. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
5. Acute respiratory distress syndrome: Study IDs surgical patients at risk
6. A gene within a gene contributes to the aggressiveness of acute myeloid leukemia
7. Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids
8. New Residential Post-Acute Facility Specializing in Traumatic Brain Injury and Spinal Cord Injury Opens in Mount Dora; Expected to Employ 175
9. EpiCast Report: Acute Ischemic Stroke - Epidemiology Forecast to 2022
10. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
11. Mayo Clinic-led study: 2 drugs do not improve kidney function in acute heart failure patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... , ... The producers of Enterprises TV are pleased to present ... world of instantaneous consumption proves very convenient for businesses. With new technologies constantly becoming ... which pollutes our air, water, and soil. It can also threaten the lives of ...
(Date:2/13/2016)... , ... February 13, 2016 , ... In the early ... They’ll groom themselves to perfection, go out of their way to be romantic, and ... just take a look at any online dating profile. , A recent study ...
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed ... pharmaceutical products, garnering increased attention from all stakeholders in the development of new ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... that nominations have closed for the ISE Southeast Awards 2016. Finalists and winners ... at the ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
(Date:2/11/2016)... -- Stem cells are primitive cells found in all ... capacity to differentiate into mature cell types Stem cells ... mouse embryonic stem cells were derived from embryos in ... first culturing of embryonic stem cells from non-human primates ... 2006 As a result of these discoveries, stem cells ...
Breaking Medicine Technology: